Blood group and Rhesus antigens among Blood donors attending the Central Blood Bank, Sudan

Background: It is well known that the Rhesus system remains the second most clinically important blood group system after the ABO. There is no published work regarding the frequency of various Rhesus antigens among Sudanese population.Objectives: In order to minimize Rhesus allo-immunization among blood recipients a cross sectional study was conducted to determine the frequency of various Rhesus antigens among the blood donors attending the Central Blood Bank in Khartoum.Methods: Two hundred male blood donors were enrolled in the study. ABO and Rhesus typing were performed using the classical slide method and gel micro typing system.Results: The frequency percentage of ABO blood phenotypes in the total samples were as follows: O(51.5%), A (29.5%), B (16%), and AB (6%); whereas the frequency percentage of Rh antigens were D (93%), e (79.5%), c (68.5%), C, (27%), E (18.5%).Conclusion: We concluded that the frequency of the Rh antigens can be shown in this order D > e > c > C > E. Special precautions need to be undertaken to minimize any possible allo-immunization by such antigens.Keywords: Frequency, Rhesus antigens, phenotyping, Blood group

Toward Sharing Brain Images: Differentially Private TOF-MRA Images With Segmentation Labels Using Generative Adversarial Networks

Sharing labeled data is crucial to acquire large datasets for various Deep Learning applications. In medical imaging, this is often not feasible due to privacy regulations. Whereas anonymization would be a solution, standard techniques have been shown to be partially reversible. Here, synthetic data using a Generative Adversarial Network (GAN) with differential privacy guarantees could be a solution to ensure the patient's privacy while maintaining the predictive properties of the data. In this study, we implemented a Wasserstein GAN (WGAN) with and without differential privacy guarantees to generate privacy-preserving labeled Time-of-Flight Magnetic Resonance Angiography (TOF-MRA) image patches for brain vessel segmentation. The synthesized image-label pairs were used to train a U-net which was evaluated in terms of the segmentation performance on real patient images from two different datasets. Additionally, the Fréchet Inception Distance (FID) was calculated between the generated images and the real images to assess their similarity. During the evaluation using the U-Net and the FID, we explored the effect of different levels of privacy which was represented by the parameter ϵ. With stricter privacy guarantees, the segmentation performance and the similarity to the real patient images in terms of FID decreased. Our best segmentation model, trained on synthetic and private data, achieved a Dice Similarity Coefficient (DSC) of 0.75 for ϵ = 7.4 compared to 0.84 for ϵ = ∞ in a brain vessel segmentation paradigm (DSC of 0.69 and 0.88 on the second test set, respectively). We identified a threshold of ϵ <5 for which the performance (DSC <0.61) became unstable and not usable. Our synthesized labeled TOF-MRA images with strict privacy guarantees retained predictive properties necessary for segmenting the brain vessels. Although further research is warranted regarding generalizability to other imaging modalities and performance improvement, our results mark an encouraging first step for privacy-preserving data sharing in medical imaging

BRAVE-NET: Fully Automated Arterial Brain Vessel Segmentation in Patients With Cerebrovascular Disease

Introduction: Arterial brain vessel assessment is crucial for the diagnostic process in patients with cerebrovascular disease. Non-invasive neuroimaging techniques, such as time-of-flight (TOF) magnetic resonance angiography (MRA) imaging are applied in the clinical routine to depict arteries. They are, however, only visually assessed. Fully automated vessel segmentation integrated into the clinical routine could facilitate the time-critical diagnosis of vessel abnormalities and might facilitate the identification of valuable biomarkers for cerebrovascular events. In the present work, we developed and validated a new deep learning model for vessel segmentation, coined BRAVE-NET, on a large aggregated dataset of patients with cerebrovascular diseases. Methods: BRAVE-NET is a multiscale 3-D convolutional neural network (CNN) model developed on a dataset of 264 patients from three different studies enrolling patients with cerebrovascular diseases. A context path, dually capturing high- and low-resolution volumes, and deep supervision were implemented. The BRAVE-NET model was compared to a baseline Unet model and variants with only context paths and deep supervision, respectively. The models were developed and validated using high-quality manual labels as ground truth. Next to precision and recall, the performance was assessed quantitatively by Dice coefficient (DSC); average Hausdorff distance (AVD); 95-percentile Hausdorff distance (95HD); and via visual qualitative rating. Results: The BRAVE-NET performance surpassed the other models for arterial brain vessel segmentation with a DSC = 0.931, AVD = 0.165, and 95HD = 29.153. The BRAVE-NET model was also the most resistant toward false labelings as revealed by the visual analysis. The performance improvement is primarily attributed to the integration Hilbert et al. Fully-Automated Arterial Brain Vessel Segmentation of the multiscaling context path into the 3-D Unet and to a lesser extent to the deep supervision architectural component. Discussion: We present a new state-of-the-art of arterial brain vessel segmentation tailored to cerebrovascular pathology. We provide an extensive experimental validation of the model using a large aggregated dataset encompassing a large variability of cerebrovascular disease and an external set of healthy volunteers. The framework provides the technological foundation for improving the clinical workflow and can serve as a biomarker extraction tool in cerebrovascular diseases

Measurement of the eta-Meson Mass using psi(2S) --> eta J/psi

We measure the mass of the eta meson using psi(2S) --> eta J/psi events acquired with the CLEO-c detector operating at the CESR e+e- collider. Using the four decay modes eta --> gamma gamma, 3pi0, pi+pi-pi0, and pi+pi-gamma, we find M(eta)=547.785 +- 0.017 +- 0.057 MeV, in which the first uncertainty is statistical and the second systematic. This result has an uncertainty comparable to the two most precise previous measurements and is consistent with that of NA48, but is inconsistent at the level of 6.5sigma with the much smaller mass obtained by GEM.Comment: 10 pages postscript,also available through http://www.lns.cornell.edu/public/CLNS/2007/, Submitted to PR

Suppressed Decays of D_s^+ Mesons to Two Pseudoscalar Mesons

Using data collected near the Ds*+ Ds- peak production energy Ecm = 4170 MeV by the CLEO-c detector, we study the decays of Ds+ mesons to two pseudoscalar mesons. We report on searches for the singly-Cabibbo-suppressed Ds+ decay modes K+ eta, K+ eta', pi+ K0S, K+ pi0, and the isospin-forbidden decay mode Ds+ to pi+ pi0. We normalize with respect to the Cabibbo-favored Ds+ modes pi+ eta, pi+ eta', and K+ K0S, and obtain ratios of branching fractions: Ds+ to K+ eta / Ds+ to pi+ eta = (8.9 +- 1.5 +- 0.4)%, Ds+ to K+ eta' / Ds+ to pi+ eta' = (4.2 +- 1.3 +- 0.3)%, Ds+ to pi+ K0S / Ds+ to K+ K0S = (8.2 +- 0.9 +- 0.2)%, Ds+ to K+ pi0 / Ds+ to K+ K0S = (5.0 +- 1.2 +- 0.6)%, and Ds+ to pi+ pi0 / Ds+ to K+ K0S < 4.1% at 90% CL, where the uncertainties are statistical and systematic, respectively.Comment: 9 pages postscript,also available through http://www.lns.cornell.edu/public/CLNS/2007/, Submitted to PR

Measurement of the Decay Constant fDS+f_D{_S^+} using $D_S^+ --> ell^+ nu

We measure the decay constant fDs using the Ds -> l+ nu channel, where the l+ designates either a mu+ or a tau+, when the tau+ -> pi+ nu. Using both measurements we find fDs = 274 +-13 +- 7 MeV. Combining with our previous determination of fD+, we compute the ratio fDs/fD+ = 1.23 +- 0.11 +- 0.04. We compare with theoretical estimates.Comment: 6 pages postscript,also available through http://www.lns.cornell.edu/public/CLNS/2007

Search for Lepton Flavor Violation in Upsilon Decays

In this Letter we describe a search for lepton flavor violation (LFV) in the bottomonium system. We search for leptonic decays of Upsilon(nS)(n=1,2, and 3) into muon and tau using the data collected with the CLEO III detector. We identify the tau lepton using its leptonic decay into electron and utilize multidimensional likelihood fitting with PDF shapes measured from independent data samples. We report our estimates of 95% CL upper limits on LFV branching fractions of Upsilon mesons. We interpret our results in terms of the exclusion plot for the energy scale of a hypothetical new interaction versus its effective LFV coupling in the framework of effective field theory.Comment: 10 pages, 3 figures, available through http://www.lns.cornell.edu/public/CLNS/, submitted to PR

Measurement of Absolute Hadronic Branching Fractions of D Mesons and e^+ e^- --> D D-bar Cross Sections at the psi(3770)

Using 281 /pb of e^+ e^- collisions recorded at the psi(3770) resonance with the CLEO-c detector at CESR, we determine absolute hadronic branching fractions of charged and neutral D mesons using a double tag technique. Among measurements for three D^0 and six D^+ modes, we obtain reference branching fractions B(D^0 --> K^-pi^+) = (3.891 +- 0.035 +- 0.059 +- 0.035)% and B(D^+ --> K^-pi^+pi^+) = (9.14 +- 0.10 +- 0.16 +- 0.07)%, where the first uncertainty is statistical, the second is all systematic errors other than final state radiation (FSR), and the third is the systematic uncertainty due to FSR. We include FSR in these branching fractions by allowing for additional unobserved photons in the final state. Using an independent determination of the integrated luminosity, we also extract the cross sections sigma(e+e- --> D^0 D^0-bar) = (3.66+- 0.03 +- 0.06) nb and sigma(e+e- --> D^+ D^-) = (2.91+- 0.03 +- 0.05) nb at a center of mass energy, E_cm = 3774 +- 1 MeV.Comment: 47 pages, postscript also available through this http://www.lns.cornell.edu/public/CLNS/2007/, to be published in PRD, updated branching fractions using B(KS0 --> pi+ pi-) from PDG 2007, and updated text in response to the PRD reviewe

Molecular markers of anti-malarial drug resistance in Lahj Governorate, Yemen: baseline data and implications

<p>Abstract</p> <p>Background</p> <p>This is an investigation of anti-malarial molecular markers coupled with a therapeutic efficacy test of chloroquine (CQ) against falciparum malaria in an area of unstable malaria in Lahj Governorate, Yemen. The study was aimed at assessment of therapeutic response to CQ and elucidation of baseline information on molecular markers for <it>Plasmodium falciparum </it>resistance against CQ and sulphadoxine/pyrimethamine (SP).</p> <p>Methods</p> <p>Between 2002 and 2003 the field test was conducted according to the standard WHO protocol to evaluate the therapeutic efficacy of CQ in 124 patients with falciparum malaria in an endemic area in Lahj Governorate in Yemen. Blood samples collected during this study were analysed for <it>P. falciparum </it>chloroquine resistance transporter gene (<it>pfcrt</it>)-76 polymorphisms, mutation <it>pfcrt-</it>S163R and the antifolate resistance-associated mutations dihydrofolate reductase (<it>dhfr</it>)-C59R and dihydropteroate synthase (<it>dhps</it>)-K540E. Direct DNA sequencing of the <it>pfcrt </it>gene from three representative field samples was carried out after DNA amplification of the 13 exons of the <it>pfcrt </it>gene.</p> <p>Results</p> <p>Treatment failure was detected in 61% of the 122 cases that completed the 14-day follow-up. The prevalence of mutant <it>pfcrt </it>T76 was 98% in 112 amplified pre-treatment samples. The presence of <it>pfcrt </it>T76 was poorly predictive of <it>in vivo </it>CQ resistance (PPV = 61.8%, 95% CI = 52.7-70.9). The prevalence of <it>dhfr </it>Arg-59 mutation in 99 amplified samples was 5%, while the <it>dhps </it>Glu-540 was not detected in any of 119 amplified samples. Sequencing the <it>pfcrt </it>gene confirmed that Yemeni CQ resistant <it>P. falciparum </it>carry the old world (Asian and African) CQ resistant haplotype CVIETSESI at positions 72,73,74,75,76,220,271, 326 and 371.</p> <p>Conclusion</p> <p>This is the first study to report baseline information on the characteristics and implications of anti-malarial drug resistance markers in Yemen. It is also the first report of the haplotype associated with CQR <it>P. falciparum </it>parasites from Yemen. Mutant <it>pfcrt</it>T76 is highly prevalent but it is a poor predictor of treatment failure in the study population. The prevalence of mutation <it>dhfr</it>Arg59 is suggestive of emerging resistance to SP, which is currently a component of the recommended combination treatment of falciparum malaria in Yemen. More studies on these markers are recommended for surveillance of resistance in the study area.</p